Pair of Federal Circuit Decisions Address Standing to Appeal Adverse IPR Decision
In 2018 and 2019, ModernaTx, Inc. (Moderna) filed a pair of inter partes review petitions challenging the validity of two patents generally directed to RNA technology owned by Arbutus Biopharma Corp.
This premium content is locked for The Intellectual Property Strategist subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.